VRDN
VRDN clinical trials: Viridian Therapeutics, Inc.\DE
Every trial on ClinicalTrials.gov where Viridian Therapeutics, Inc.\DE is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 9
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
VRDN on the catalyst calendar · VRDN registry changes
- Primary completion Apr 2027Sponsor estimatePhase 4NCT07832136An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to TeprotumumabViridian Therapeutics, Inc. · Thyroid Eye DiseaseNot yet recruitingVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 12, 2026ActualPhase 3NCT06625411An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseActive, not recruitingVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 4, 2026ActualPhase 3NCT06625398An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseActive, not recruitingVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2025ActualPhase 3NCT06384547A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseCompletedVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2025ActualPhase 3NCT06179875An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301Viridian Therapeutics, Inc. · Thyroid Eye DiseaseCompletedVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 4, 2024ActualPhase 3NCT06021054An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseCompletedVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 15, 2024ActualPhase 3NCT05176639A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseCompletedVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 28, 2026ActualPhase 3NCT07155668A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye DiseaseCompletedVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2026ActualPhase 3NCT06812325A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)Viridian Therapeutics, Inc. · Thyroid Eye Disease (TED)Active, not recruitingVRDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner